MAPT and Cerebral atrophy: Future studies should incorporate neuroimaging markers (e.g., cerebral atrophy patterns and white matter hyperintensity volumes) and CSF biomarkers (e.g., Aβ42 and p‐tau) to assess whether Alzheimer's pathology or vascular burden modifies PLPH susceptibility.